舒泰神(300204) - 2021 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2021 reached ¥153,679,651.05, an increase of 18.02% year-over-year, and cumulative revenue for the year-to-date was ¥426,311,803.88, up 43.93% compared to the same period last year[3] - Net profit attributable to shareholders was -¥65,999,771.49, a decrease of 183.87% year-over-year, with year-to-date net profit at -¥125,811,196.48, down 28.08%[3] - Basic earnings per share for Q3 2021 was -¥0.14, a decline of 180.00% year-over-year, and year-to-date basic earnings per share was -¥0.27, down 28.57%[4] - The net loss for the quarter was CNY 125,811,196.48, compared to a net loss of CNY 98,228,383.78 in the same quarter last year, reflecting a decline of 28.1%[35] - The total comprehensive loss for the quarter was CNY 180,407,452.82, compared to a loss of CNY 87,256,275.87 in the previous year[36] Research and Development - Research and development expenses increased by ¥98,133,251.60, representing a 69.47% rise year-over-year, due to ongoing R&D projects[10] - Research and development expenses totaled 241.75 million yuan in the first nine months of 2021, reflecting a significant increase of 65.00% compared to the previous year[19] - Research and development expenses surged to CNY 239,384,890.17, representing an increase of 69.5% compared to CNY 141,251,638.57 in the previous year[35] - The company announced that the injection of STSP-0601 entered Phase II clinical trials after successfully completing Phase I trials in August 2021[20] - The Phase I clinical trial results for STSP-0601 indicated good safety and tolerability in hemophilia patients with inhibitors, showing a dose-dependent effect on coagulation function[20] - BDB-001 injection received new drug clinical trial approval for ANCA-associated vasculitis in August 2021[21] - STSA-1005 injection obtained FDA clinical trial permission for severe COVID-19 treatment in September 2021[22] - STSA-1002 injection is the first project to achieve dual submission and approval in both China and the US for severe COVID-19 treatment[22] - The first subject in the STSA-1002 injection Phase I clinical trial was dosed in the US in September 2021[24] - The company plans to accelerate clinical development and commercialization of products in key areas such as infectious diseases and autoimmune diseases[25] - The company is actively promoting clinical research and development of drugs to meet unmet clinical needs[25] Cash Flow and Financial Position - Cash flow from operating activities showed a net outflow of -¥115,519,046.54, a decrease of 44.49% year-to-date[3] - Cash inflows from operating activities totaled CNY 431,388,799.42, compared to CNY 360,351,589.34 in the previous year[39] - The net cash flow from operating activities was -115,519,046.54 CNY, compared to -79,947,970.04 CNY in the previous year, indicating a decline in operational cash generation[40] - The net cash flow from investment activities improved to 130,725,769.58 CNY from -129,044,834.01 CNY year-over-year, reflecting a positive turnaround in investment returns[40] - Total cash and cash equivalents at the end of the period were 120,533,483.86 CNY, down from 191,141,624.02 CNY in the same quarter last year, showing a decrease of approximately 37%[41] - Cash inflow from financing activities was -35,203,488.77 CNY, a significant decrease from 47,665,466.66 CNY in the prior year, indicating challenges in raising funds[40] - The company received 18,312,960.00 CNY from investment absorption, marking a new source of cash inflow[40] - The cash outflow for investment activities totaled 668,249,297.02 CNY, down from 972,132,836.86 CNY, reflecting a reduction in capital expenditures[40] - The company experienced a foreign exchange loss of -44,008.74 CNY, which impacted the overall cash position[41] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥1,674,624,141.61, a decrease of 9.78% from the end of the previous year[4] - As of September 30, 2021, total current assets decreased to CNY 741.12 million from CNY 903.32 million at the end of 2020, a decline of approximately 17.96%[30] - Total assets decreased to CNY 1.67 billion as of September 30, 2021, down from CNY 1.86 billion at the end of 2020, a reduction of about 9.79%[30] - Total current liabilities decreased to CNY 167.51 million from CNY 208.20 million at the end of 2020, a decrease of approximately 19.54%[31] - Non-current liabilities totaled CNY 62.05 million as of September 30, 2021, compared to CNY 60.50 million at the end of 2020, an increase of about 2.56%[31] - The company's total equity attributable to shareholders decreased to CNY 1,445,056,936.91 from CNY 1,587,506,217.45 year-over-year[32] - The total liabilities and equity amounted to CNY 1,674,624,141.61, down from CNY 1,856,205,798.74 in the previous year[32] - Total liabilities increased to 268,699,581.29 CNY from 278,742,164.28 CNY, indicating a slight reduction in overall debt levels[45] - The company’s equity attributable to shareholders was 1,587,506,217.45 CNY, remaining stable compared to the previous year[46]